危险系数
医学
肾脏疾病
混淆
置信区间
观察研究
锂(药物)
肾功能
双相情感障碍
内科学
比例危险模型
风险因素
相对风险
重症监护医学
队列研究
风险评估
低风险
心脏病学
共病
绝对风险降低
蛋白尿
疾病
荟萃分析
作者
Hammza Jabbar Abdl Sattar Hamoudi,Marsal Sanches,Jair C. Soares
标识
DOI:10.1097/yco.0000000000001134
摘要
PURPOSE OF REVIEW: Lithium remains the most effective long-term treatment for bipolar disorder, but concern about chronic kidney disease (CKD) continues to limit its use in older adults, in whom renal reserve is already reduced and competing renal risk factors are common. Whether that concern is proportionate, and whether risk depends on serum concentration or on the comparator chosen, remains unsettled. We synthesized the observational evidence on lithium and CKD in adults aged 50 and over with bipolar disorder. RECENT FINDINGS: Across 6 cohorts, lithium was associated with a higher risk of CKD than nonlithium exposure (pooled hazard ratio 1.62, 95% confidence interval 1.25-2.11), although heterogeneity was substantial and the prediction interval crossed the null. Risk tracked with serum concentration: a higher-versus-lower contrast across 5 cohorts gave a pooled hazard ratio of 2.07 (1.47-2.91), the least heterogeneous analysis and the only one whose prediction interval lay entirely above the null. Against valproate the association attenuated to 1.39 (0.77-2.51). Hard kidney-failure endpoints were too few to estimate reliably. No study reported cognition in relation to renal function. No study was at low risk of bias, and confounding was the dominant concern. SUMMARY: In older adults with bipolar disorder, lithium is associated with a modest, concentration-dependent increase in CKD risk that narrows when valproate rather than nonuse is the comparator. The evidence is observational and confounding-prone, and supports minimising serum concentration and monitoring renal function against age-appropriate thresholds rather than avoiding lithium.
科研通智能强力驱动
Strongly Powered by AbleSci AI